For the Inventor, By the Inventor

Enter assignee name

Fuso Pharmaceutical Industries, Ltd.

USPTO Granted Patents = 107

CIPO Patents = 11

EPO Patents = 39

Forward Citations = 677

Loading Chart...

Loading Chart...

156 inventors (with patents filed for the assignee):

Akio Matsuhisa (14 out of 16 patents)

Nobutaka Wakamiya (14 out of 14 patents)

Masahiro Asakura (10 out of 11 patents)

4. Keiichi Yamamoto (10 out of 33 patents)

5. Shinji Yamasaki (9 out of 9 patents)

6. Hiroyuki Keshi (9 out of 9 patents)

7. Yasuhiko Suzuki (8 out of 8 patents)

8. Hirotsugu Uehara (8 out of 9 patents)

9. Akira Okui (7 out of 7 patents)

10. Katsuya Kominami (7 out of 7 patents)

11. Nozomi Yamaguchi (7 out of 14 patents)

12. Shinichi Mitsui (7 out of 7 patents)

13. Hidetoshi Uemura (6 out of 6 patents)

14. Soji Eda (6 out of 7 patents)

15. Tsuneya Ohno (6 out of 9 patents)

Core Competencies:

Cardioplegic Solution

Lipid-Peroxidation-Induced Diseases

Anti-PD-L1 Antibody

T-Type Calcium Channel Inhibitor

Disulfide-Type HMGB1

Diabetic Nephropathy

High Purity Heparin

Adenovirus Vector

Protein Production

Immune Checkpoint Inhibitory Action

Sodium Diacetate Crystal

Trophectodermal Gene Transfer

107 patents: Sort by Forward Citations

1. 12472299 - Reservoir assembly for providing cardioplegic solution containing bicarbonate ion, and method for manufacturing the same (2025-11-18),

2. 12306164 - Therapeutic drug for lipid-peroxidation-induced diseases and screening method for therapeutic drugs for lipid-peroxidation-induced diseases (2025-05-20),

3. 11781146 - Vector including a translation-impaired dihydrofolate reductase gene cassette and ubiquitously acting chromatin opening element (2023-10-10),

4. 11725002 - Detection reagents and kit for identifying oxidized state and glycated state of low-density lipoproteins (2023-08-15),

5. 11697686 - Anti-PD-L1 antibody for detecting PD-L1 (2023-07-11),

6. 11609238 - Method for detecting a radical compound derived from a lipid and a compound derived from the radical compound (2023-03-21),

7. 11591297 - Compound having PD-L1 expression-suppressing action (2023-02-28),

8. 11519893 - Therapeutic drug for lipid-peroxidation-induced diseases and screening method for therapeutic drugs for lipid-peroxidation-induced diseases (2022-12-06),

9. 11479537 - T-type calcium channel inhibitor (2022-10-25),

10. 11312773 - Anti-PD-L1 antibody (2022-04-26),

11. 11198730 - Anti-LAG-3 antibody (2021-12-14),

12. 11193162 - Nucleic acid detection or quantification method using mask oligonucleotide, and device for same (2021-12-07),

13. 11174310 - Disulfide-type HMGB1-specific antibody, method for measuring disulfide-type HMGB1 and kit for said measurement, and measurement method capable of quantitating all of HMGB1 molecules including reduced HMGB1, disulfide-type HMGB1 and thrombin-cleavable HMGB1 and kit for said measurement (2021-11-16),

14. 11160286 - Method for producing disinfected liver (2021-11-02),

15. 11040937 - Amide derivative (2021-06-22),

Fuso Pharmaceutical Industries, Ltd. is a leading pharmaceutical company specializing in the research, development, and production of innovative healthcare products. With a commitment to improving global health, Fuso Pharma is dedicated to delivering high-quality medicines that enhance the well-being of individuals. Through continuous innovation and collaboration, Fuso Pharma strives to contribute to the advancement of healthcare worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

107 Patents

#106 in Osaka

#1,053 in Japan

#7,134 in the World

Fuso Pharmaceutical Industries, Ltd.

Forward Citations = 677

156 inventors:

Akio Matsuhisa (14 out of 16 patents)

Nobutaka Wakamiya (14 out of 14 patents)

Masahiro Asakura (10 out of 11 patents)

4. Keiichi Yamamoto (10 out of 33 patents)

5. Shinji Yamasaki (9 out of 9 patents)

Please report any incorrect information to support@idiyas.com

Loading…